ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.01 USD
+0.01 (0.50%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $2.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Brokerage Reports
0 items in cart
ProQR Therapeutics N.V. [PRQR]
Reports for Purchase
Showing records 41 - 51 ( 51 total )
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Believe QR-010 Results Establish POC and Will Likely Trigger Partnership Signing; Reit Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Our View on the NPD Update: Positive Data Are Positive Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2016: Hot Topics and Abstracts of InterestThis report contains brief updates on the following: NVLS, PRQR, PTI, VRTX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Our Thoughts on Catalysts, Pipeline, and Value in 2016
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Spotlight on NACFC 2015: Hot Topics and Abstracts of Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
ProQR is Now a Clinical-Stage CF Company with NPD Data Up Next; Reit Buy and $40PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
After a Year of Record Execution, the Company Heads to POC Value-Drivers in 2015
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
$15M Down, $3.285B To Go: We Look at Shire?s Approach to CF Therapy Following Grant from CF Foundation Therapeutics
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A